Revenue nearly doubled at digital pharmacy TelyRx, but it lost $2.7 million from operations.

TelyRx reported Q3 2026 revenue of $23.1M, up from $12.3M in Q3 2025, but net loss from operations widened to $2.7M from $0.9M. Adjusted EBITDA loss narrowed to $1.3M from $0.4M. The company launched a new brand and website, expanded its formulary, and plans to triple capacity in Clearwater, Florida.

Original reporting
Published Nov 5, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$TELYF
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Med
01

Why it matters

The earnings release provides fresh data for traders evaluating small‑cap digital health stocks, highlighting both top‑line growth and ongoing loss challenges.

02

Market read

First‑report earnings for a micro‑cap health‑tech firm; modest trading relevance but new data for valuation models.

03

What to watch

The company’s cash balance surged, providing runway; however, the need for additional financing remains uncertain.

Relevance 6/10Novelty 7/10Timing: today

Background

TelyRx Holdings Inc. released its Q3 2026 financial results, showing revenue growth to $23.1 M and a net loss from operations of $2.7 M.

Market effects

Digital pharmacy and tele‑health providers may see heightened investor interest as revenue growth outpaces loss reduction.

Primarily affects U.S. small‑cap investors; limited broader market effect.

Limited to niche health‑tech niche; no major global market shift.

Counterpoint

Despite revenue doubling, widening operating loss could signal cash‑burn concerns that outweigh growth headlines.

Key entities

  • TelyRx Holdings Inc.

    Digital pharmacy platform reporting Q3 2026 results.

Related articles

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.

$NVDAHighAI 9/10

Nvidia's $130 Billion Forecast Sparks Fresh AI Stock Rally

Nvidia's shares rose 2% premarket after reporting Q3 sales of $115.84B, up 4x, and raising its fiscal 2028 sales growth target to ~75%. The company also guided to a gross margin of 71-72% for the current quarter. AI-related stocks also gained. Nvidia's board is searching for a permanent CEO after rejecting Jensen Huang's return. The company excluded future China shipments from its projections.